HC Wainwright Reaffirms "Buy" Rating for ImmunityBio (NASDAQ:IBRX)

HC Wainwright reiterated their buy rating on shares of ImmunityBio (NASDAQ:IBRX - Free Report) in a research note published on Monday,Benzinga reports. HC Wainwright currently has a $8.00 price objective on the stock. HC Wainwright also issued estimates for ImmunityBio's Q2 2025 earnings at ($0.09) EPS, Q3 2025 earnings at ($0.09) EPS, Q4 2025 earnings at ($0.10) EPS, FY2025 earnings at ($0.44) EPS, FY2026 earnings at ($0.26) EPS, FY2027 earnings at ($0.07) EPS, FY2028 earnings at $0.12 EPS and FY2029 earnings at $0.34 EPS.

Separately, D. Boral Capital reissued a "buy" rating and issued a $30.00 price objective on shares of ImmunityBio in a research note on Monday, May 12th. One analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $12.19.

ImmunityBio Stock Up 6.4%

Shares of IBRX stock traded up $0.17 during trading hours on Monday, reaching $2.84. The company's stock had a trading volume of 8,708,023 shares, compared to its average volume of 5,479,200. ImmunityBio has a fifty-two week low of $1.83 and a fifty-two week high of $8.07. The firm's 50 day simple moving average is $2.64 and its 200-day simple moving average is $3.30. The company has a market capitalization of $2.51 billion, a price-to-earnings ratio of -3.09 and a beta of 0.33.

ImmunityBio (NASDAQ:IBRX - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.03). The company had revenue of $16.52 million during the quarter, compared to analyst estimates of $17.50 million. Sell-side analysts predict that ImmunityBio will post -0.92 earnings per share for the current year.

Institutional Investors Weigh In On ImmunityBio

A number of institutional investors have recently added to or reduced their stakes in the business. Barclays PLC lifted its holdings in shares of ImmunityBio by 127.4% during the third quarter. Barclays PLC now owns 361,036 shares of the company's stock worth $1,344,000 after purchasing an additional 202,248 shares during the period. Mutual Advisors LLC bought a new stake in shares of ImmunityBio in the 4th quarter valued at about $41,000. China Universal Asset Management Co. Ltd. increased its stake in shares of ImmunityBio by 10.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 147,754 shares of the company's stock valued at $378,000 after buying an additional 13,788 shares during the period. Stephens Inc. AR bought a new position in shares of ImmunityBio during the fourth quarter worth about $26,000. Finally, New York State Common Retirement Fund lifted its stake in shares of ImmunityBio by 62.8% in the fourth quarter. New York State Common Retirement Fund now owns 32,418 shares of the company's stock worth $83,000 after acquiring an additional 12,500 shares during the period. 8.58% of the stock is owned by institutional investors.

About ImmunityBio

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.